PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue European Journal of Cancer Année : 2017

PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer

Anthony Gonçalves

Domaines

Cancer
Fichier non déposé

Dates et versions

hal-03623711 , version 1 (29-03-2022)

Identifiants

Citer

Mathilde Guerin, Keyvan Rezai, Nicolas Isambert, Mario Campone, Aurélie Autret, et al.. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. European Journal of Cancer, 2017, 86, pp.28-36. ⟨10.1016/j.ejca.2017.08.025⟩. ⟨hal-03623711⟩
23 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More